Results 51 to 60 of about 3,492 (143)
Low‐Dose Cytarabine Plus G‐CSF Induction in Pediatric M2 Acute Myeloid Leukemia: A Multicenter Study
Cancer Medicine, Volume 15, Issue 10, October 2026.ABSTRACT This retrospective secondary analysis of the multicenter randomized CALS III‐AML18 trial evaluated the efficacy and safety of low‐dose chemotherapy (LDC) compared with standard‐dose chemotherapy (SDC) in children with M2 acute myeloid leukemia (AML‐M2). A total of 221 children were included, with 109 in the LDC arm and 112 in the SDC arm.
Wenxin Ou +21 more
wiley +1 more source
, 2022 BackgroundThe distribution of RUNX1-RUNXT1, PML-RARA, CBFB-MYH11, BCR-ABL1p210, and KMT2A-MLLT3 in the pediatric population with acute myeloid leukemia (AML) in many countries of Latin America is largely unknown.
Jorge Alfonso Martín-Trejo (8321058) +30 more
core +1 more source
Journal of Research in Medical Sciences, 2017 Background: The Wilms tumor 1 (WT1) gene is originally defined as a tumor suppressor gene and a transcription factor that overexpressed in leukemic cells.
Hossein Ayatollahi +8 more
doaj +1 more source
Fusion Gene Detection Using Whole-Exome Sequencing Data in Cancer Patients
Frontiers in Genetics, 2022 Several fusion genes are directly involved in the initiation and progression of cancers. Numerous bioinformatics tools have been developed to detect fusion events, but they are mainly based on RNA-seq data.
Wenjiang Deng +8 more
doaj +1 more source
Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.ABSTRACT Background Survival after relapse in pediatric acute myeloid leukemia (AML) remains poor, highlighting the critical importance of identifying prognostic factors to guide optimal relapse management. Methods We investigated the prognostic impact of multiparameter flow cytometry (MFC) measurable residual disease (MRD) in 188 patients with first ...
Camilla Poulsen +21 more
wiley +1 more source
Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia
Frontiers in Oncology, 2018 Acute myeloid leukemia (AML) is a collection of hematologic malignancies with specific driver mutations that direct the pathology of the disease. The understanding of the origin and function of these mutations at early stages of transformation is ...
John Anto Pulikkan +1 more
doaj +1 more source
HemaSphere, Volume 10, Issue 9, September 2026.Abstract Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a curative treatment option for a significant proportion of patients with acute myeloid leukemia (AML), and it is generally recommended when the relapse risk without allo‐HSCT outweighs the estimated non‐relapse mortality significantly.
Alberto Hernández‐Sánchez +28 more
wiley +1 more source
Insertion as an alternative mechanism of CBFB-MYH11 gene fusion in a new case of acute myeloid leukemia with an abnormal chromosome 16 [PDF]
, 2012 Case report of a translocation : Insertion as an alternative mechanism of CBFB-MYH11 gene fusion in a new case of acute myeloid leukemia with an abnormal chromosome ...
Mohamed, AN, Kulkarni, V, Hussein, Y
core +1 more source
DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. [PDF]
PLoS ONE, 2010 Aberrant promoter DNA methylation has been shown to play a role in acute myeloid leukemia (AML) pathophysiology. However, further studies to discuss the prognostic value and the relationship of the epigenetic signatures with defined genomic ...
Sara Alvarez +18 more
doaj +1 more source
Passenger variants as pan‐clonal markers of pediatric AML: Implications for molecular MRD
HemaSphere, Volume 10, Issue 8, August 2026.Abstract A streamlined, sensitive, and universal molecular method for MRD detection in pediatric AML remains an unmet clinical need. Here, we propose a novel approach based on tracking somatic non‐coding passenger variants. Using whole‐genome sequencing (WGS) of diagnostic bone marrow DNA, we identify patient‐specific somatic passenger variants, which ...
Ruth Shiloh +20 more
wiley +1 more source